Pivotal Therapeutics Inc. is to be Featured on CEO Clips on CBC's The Documentary Channel

WOODBRIDGE, May 11, 2015 /CNW/ - Pivotal Therapeutics Inc. (CSE:PVO; OTCQX:PVTTF), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today the company and Mrs. Rachelle MacSweeney, Co-Founder, President and COO will be featured on CEO Clips on CBC's The Documentary Channel. CEO Clips, a series which profiles the most innovative publicly traded companies in North America, will feature Pivotal on The Documentary Channel beginning May 11, 2015, Monday through Friday, throughout the day and evenings. It can also be viewed online via this link: http://www.b-tv.com/pivotal-therapeutics-ceo-clip/.

In addition it will be posted on these financial portals: BNN.ca Finance, Canadian Business Journal, Thomson Reuters Insider Network, MSN Money , Stockhouse, YouTube, Blinkx, on our stock symbol page as well as on CEO Clips.

About CBC's The Documentary Channel

"Documentary is a digital television station devoted to showing the best documentaries from Canada and around the world. With its special emphasis on feature length films, watching Documentary is like having a cinema in your own living room, showing award winning films twenty-four hours a day, seven days a week."

About Pivotal Therapeutics Inc.

Pivotal Therapeutics is a publicly traded (CSE:PVO; OTCQX:PVTTF), specialty pharmaceutical company with a focus on cardiovascular disease and overall health. Pivotal Therapeutics' lead product VASCAZEN^® is a prescription only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications. OMAZEN^® is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in each capsule for the maintenance of good health. OMAZEN^® is a patented product available for sale and distribution in Canada for the professional market. BeneFishial™ is the first product in Pivotal's new nutraceutical product line, which has been specifically designed to be sold in the OTC direct to retail or direct to consumer markets.

Disclosure Notice
The information contained in this document is as May 11, 2015. This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Pivotal's actual results to differ materially from those projected in such forward-looking statements. These statements can be identified by the use of words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe", "project", "potential", and similar expressions with any discussion of future operating or financial performance or events. In particular, factors that could cause actual results to differ materially from those in forward looking statements include the following: Pivotal's inability to obtain additional financing on acceptable terms; growth in costs and expenses; inability to compete with others who provide comparable products; risk that the Company's products will not gain widespread market acceptance; risks relating to the Company's ability to maintain its CSE listing. Forward-looking statements speak only as of the date made and are not guarantees of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this document as a result of new information or future events or developments. The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this information.

SOURCE Pivotal Therapeutics Inc.

Company Contacts: Kristine DiMatteo, Communications and Public Relations Manager, Phone: [phone] ext. 231, E-Mail: [email protected]